HbA1c Reduction by Imeglimin (Twymeeg) In Diabetic Patient with Pancreatic Atrophy on Curved Planar Reconstruction (CPR)

Ogura K, Bando H, Kato Y, Yamashita H and Kato Y

Published on: 2023-06-22

Abstract

The patient is 55-year-old male with type 2 diabetes (T2D) and pancreatic atrophy.  Hyperglycemia was found in autumn 2022, and HbA1c showed 11.5% in December 2022. He has continued drinking alcohol about 3-4 bottles of beer for 35 years and pancreatic atrophy was detected by radiological method of Curved Planar Reconstruction (CPR) in the plain and enhanced abdominal CT scan. Administration of imeglimin (Twymeeg) brought improved glucose variability from 10.9% to 6.8% of HbA1c for 12 weeks, indicating remarkable clinical efficacy. Other medical problems included obesity (BMI 27.8 kg/m²), fatty liver, dyslipidemia and gall stone probable made of cholesterol.